📄 medicine

The Efficacy of Automated Breast Ultrasound Combined with Hand-held Ultrasound in Evaluating MRI-Detected High-Risk Non-Mass Lesions

This study demonstrates that combining automated and hand-held breast ultrasound offers superior diagnostic specificity and a higher area under the curve compared to MRI for evaluating high-risk non-mass lesions, effectively reducing unnecessary biopsies while identifying key sonographic features predictive of malignancy.

Original authors: Xiaobing Chen, Yuxuan Qiu, Xiaojing Xu, Bei Lin, Kaiyan Lou, Hongmei Ran, He Li, Lingyun Bao

Published 2026-06-28

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Xiaobing Chen, Yuxuan Qiu, Xiaojing Xu, Bei Lin, Kaiyan Lou, Hongmei Ran, He Li, Lingyun Bao

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: Finding the "Needle in the Haystack"

Imagine your breast tissue is a dense forest. Sometimes, a dangerous tree (cancer) grows there, but it doesn't look like a normal tree with a clear trunk and branches. Instead, it looks like a weird patch of tangled vines or a strange discoloration in the leaves. In medical terms, these are called Non-Mass Lesions (NMLs). They are tricky because they don't have a clear shape, making them hard to tell apart from harmless patches of vegetation (benign conditions).

The researchers wanted to solve a specific problem: How do we tell the difference between a dangerous "tangled vine" and a harmless one without cutting down every suspicious patch to check?

The Tools: Three Different Flashlights

To find these tricky patches, doctors usually use three types of "flashlights" (imaging tools):

Mammography (MG): A standard X-ray. Good for seeing hard spots, but often blind in dense forests (dense breast tissue).
MRI (Magnetic Resonance Imaging): A super-powerful, high-tech flashlight that sees almost everything. It's very good at finding the trouble spots (high sensitivity), but it's a bit paranoid. It screams "Danger!" at almost everything, even harmless patches. This leads to many unnecessary trips to the biopsy room (the "surgery" to check if it's cancer).
Ultrasound: A sound-wave flashlight.
- Hand-held (HHUS): A doctor moves a wand over the skin. It's great but depends entirely on the doctor's skill and how they hold the wand.
- Automated (ABUS): A machine that scans the whole breast and creates a perfect, 3D map from every angle. It's consistent and doesn't get tired, but it misses some details like blood flow.

The Experiment: The "Double-Check" Strategy

The researchers took 160 patients who had already been flagged by the super-powerful MRI as having "high-risk" non-mass lesions. The MRI was so sensitive it found 166 suspicious spots.

The team then asked: "What happens if we look at these same spots using a combination of the Automated Ultrasound (the 3D map) and the Hand-held Ultrasound (the detailed blood flow check)?"

They compared the results of this "Double-Check" against the final truth (the pathology report, which is the only way to know for sure if it's cancer).

The Results: Smarter, Not Just Louder

Here is what they found, using a simple analogy:

MRI is like a very loud alarm system. It goes off for almost every intruder (91.4% of the time it catches the bad guys). But, it also goes off for cats, birds, and wind (it has low specificity). Because it's so loud, it causes a lot of panic and unnecessary police visits (biopsies).
The Combined Ultrasound (ABUS + HHUS) is like a smart security guard. It still catches almost all the bad guys (87.5% sensitivity), but it is much better at ignoring the harmless stuff. It only sounds the alarm when it sees something truly suspicious.

The Key Stats:

MRI: Caught 91% of cancers, but only correctly identified 32% of benign (harmless) cases as harmless.
Combined Ultrasound: Caught 87.5% of cancers, but correctly identified 69% of benign cases as harmless.

The Takeaway: By using the combined ultrasound, doctors could stop worrying about nearly twice as many harmless cases as they could with MRI alone. This means fewer patients would need to undergo unnecessary, stressful, and costly biopsies.

What Makes a Spot Look "Bad"?

The study also looked at the "personality" of the lesions to see what features predict cancer. Think of these as the "tells" a poker player gives away:

Calcifications (Tiny Rocks): If the lesion has tiny, bright specks inside it, it's more likely to be bad.
The "Halo" Effect: If the lesion is surrounded by a bright, glowing ring (echogenic halo), it's a warning sign.
Rich Blood Flow: If the lesion is pumping a lot of blood (like a busy construction site), it's suspicious.
Segmental Distribution: If the weird patch is shaped like a slice of a pie (segmental) rather than a random blob, it's more likely to be cancer.

The Conclusion

The paper concludes that while MRI is excellent at finding these tricky, shapeless lesions, it is too "paranoid" and leads to too many unnecessary biopsies.

By adding the Automated Ultrasound (ABUS) and the Hand-held Ultrasound (HHUS) to the mix, doctors can get a clearer, more accurate picture. This combination acts like a filter, keeping the high sensitivity (not missing the cancer) but dramatically improving the specificity (correctly saying "this is safe" when it is).

In short: This new approach helps doctors avoid the "false alarms" of MRI, saving patients from unnecessary procedures while still catching the cancer.

Technical Summary: The Efficacy of Automated Breast Ultrasound Combined with Hand-held Ultrasound in Evaluating MRI-Detected High-Risk Non-Mass Lesions

Problem Statement
Breast cancer remains the most prevalent malignant tumor among women globally. While mammography, ultrasound (US), and magnetic resonance imaging (MRI) are standard screening tools, the detection and characterization of non-mass lesions (NMLs) present significant diagnostic challenges. NMLs, defined as abnormal findings lacking distinct mass characteristics, account for approximately 9.2% of breast lesions but exhibit malignancy rates ranging from 6.3% to 53.8%.

Current diagnostic limitations include:

MRI: While highly sensitive, MRI often lacks specificity in differentiating benign from malignant NMLs, leading to a high rate of unnecessary biopsies and increased patient anxiety.
Hand-held Ultrasound (HHUS): Although effective for dense breast tissue (common in East Asian populations), HHUS suffers from low specificity due to the considerable overlap in sonographic features between benign and malignant NMLs.
Standardization: There is a lack of standardized descriptive terminology and classification criteria for NMLs in ultrasound, further complicating accurate diagnosis.

Methodology
This retrospective, single-center study evaluated 160 patients (166 lesions) with breast NMLs initially classified as BI-RADS 4 or 5 by MRI at the First People's Hospital of Hangzhou (January 2019–October 2023). All lesions underwent histological confirmation via needle biopsy or surgical excision.

Imaging Protocol: Patients underwent preoperative MRI, Automated Breast Ultrasound (ABUS), and HHUS.
- MRI: Performed on a 3.0 T system with contrast enhancement.
- ABUS: Utilized a Siemens Acuson S2000 system to acquire standardized transverse, sagittal, and reconstructed coronal plane images.
- HHUS: Performed with a 18L-6HD linear array probe for radial scanning, including Doppler analysis for blood flow grading (Adler's method).
Evaluation Criteria: Two experienced radiologists independently evaluated images based on specific sonographic features: internal echo, calcifications, echogenic halo, ductal abnormalities, posterior acoustic attenuation, blood flow grading, distribution characteristics (focal, linear, segmental, regional), and the coronal convergence sign.
Statistical Analysis: Using pathological results as the gold standard, the study calculated sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Area Under the Curve (AUC) for MRI versus the combined ABUS+HHUS approach. Univariate and multivariate logistic regression analyses were performed to identify independent predictive indicators for malignancy.

Key Contributions and Results
The study demonstrates that combining ABUS with HHUS significantly improves diagnostic specificity for high-risk NMLs without compromising sensitivity compared to MRI alone.

Diagnostic Performance:
- MRI: Sensitivity 91.4%, Specificity 32.3%, AUC 0.618.
- ABUS + HHUS: Sensitivity 87.5%, Specificity 69.4%, AUC 0.784.
- The combined approach showed a statistically significant improvement in specificity ( $P < 0.0001$ ) and AUC ( $P < 0.00001$ ) compared to MRI.
Predictive Sonographic Features:
Multivariate analysis identified specific features significantly associated with malignant transformation in NMLs:
1. Calcifications: Present in 68.27% of malignant cases vs. 25.81% of benign cases ( $P < 0.0001$ ).
2. Echogenic Halo: Observed in 8.65% of malignant cases (all 9 cases were malignant) vs. 0% in benign cases ( $P = 0.0426$ ).
3. Rich Blood Flow Signals: Grade III blood flow was significantly more common in malignant lesions ( $P = 0.0009$ ).
4. Segmental Distribution: Found in 9.62% of malignant lesions and 0% of benign lesions ( $P = 0.0086$ ).
- Note: Internal echo, ductal abnormalities, and the coronal convergence sign did not show statistically significant differences between benign and malignant groups in this cohort.

Significance and Claims
The authors claim that the integration of ABUS and HHUS offers a non-invasive, cost-effective, and reliable imaging strategy to re-evaluate high-risk NMLs detected by MRI. The primary significance of this work lies in its potential to:

Reduce Unnecessary Biopsies: By improving specificity from 32.3% (MRI) to 69.4% (ABUS+HHUS), the combined modality can help clinicians avoid unnecessary invasive procedures for benign lesions.
Enhance Diagnostic Precision: The study provides evidence that specific sonographic features (calcifications, echogenic halo, rich blood flow, and segmental distribution) serve as positive predictive indicators for malignancy in NMLs.
Optimize Clinical Decision-Making: The approach leverages the reproducibility of ABUS (coronal plane assessment) and the hemodynamic capabilities of HHUS to create a more objective evaluation framework, addressing the ambiguity often found in standard ultrasound assessments of NMLs.

The study concludes that while MRI remains a sensitive screening tool, the addition of ABUS+HHUS is a superior method for differentiating benign from malignant NMLs, thereby refining the diagnostic pathway for breast cancer.